CIPHER PHARMACEUTICALS INC (CPH.CA) Fundamental Analysis & Valuation

TSX:CPH • CA17253X1050

Current stock price

18.1 CAD
-0.41 (-2.22%)
Last:

This CPH.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. CPH.CA Profitability Analysis

1.1 Basic Checks

  • In the past year CPH was profitable.
  • In the past year CPH had a positive cash flow from operations.
  • In the past 5 years CPH has always been profitable.
  • In the past 5 years CPH always reported a positive cash flow from operatings.
CPH.CA Yearly Net Income VS EBIT VS OCF VS FCFCPH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

1.2 Ratios

  • With an excellent Return On Assets value of 17.46%, CPH belongs to the best of the industry, outperforming 96.77% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 21.65%, CPH belongs to the top of the industry, outperforming 90.32% of the companies in the same industry.
  • CPH has a better Return On Invested Capital (9.24%) than 90.32% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 9.14%.
  • The 3 year average ROIC (7.38%) for CPH is below the current ROIC(9.24%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 17.46%
ROE 21.65%
ROIC 9.24%
ROA(3y)16.09%
ROA(5y)19.87%
ROE(3y)19.41%
ROE(5y)23.95%
ROIC(3y)7.38%
ROIC(5y)11.67%
CPH.CA Yearly ROA, ROE, ROICCPH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150 -200

1.3 Margins

  • Looking at the Profit Margin, with a value of 54.17%, CPH belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Profit Margin of CPH has grown nicely.
  • Looking at the Operating Margin, with a value of 33.43%, CPH belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • CPH's Operating Margin has declined in the last couple of years.
  • CPH has a better Gross Margin (80.12%) than 96.77% of its industry peers.
  • CPH's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.43%
PM (TTM) 54.17%
GM 80.12%
OM growth 3Y-14.47%
OM growth 5Y-9.91%
PM growth 3Y-25.08%
PM growth 5Y20.8%
GM growth 3Y-0.22%
GM growth 5Y-1.37%
CPH.CA Yearly Profit, Operating, Gross MarginsCPH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CPH.CA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CPH is still creating some value.
  • CPH has less shares outstanding than it did 1 year ago.
  • CPH has less shares outstanding than it did 5 years ago.
  • CPH has a better debt/assets ratio than last year.
CPH.CA Yearly Shares OutstandingCPH.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
CPH.CA Yearly Total Debt VS Total AssetsCPH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • CPH has an Altman-Z score of 8.30. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
  • CPH has a better Altman-Z score (8.30) than 96.77% of its industry peers.
  • The Debt to FCF ratio of CPH is 0.19, which is an excellent value as it means it would take CPH, only 0.19 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of CPH (0.19) is better than 96.77% of its industry peers.
  • A Debt/Equity ratio of 0.04 indicates that CPH is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.04, CPH is doing good in the industry, outperforming 74.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.19
Altman-Z 8.3
ROIC/WACC1.06
WACC8.68%
CPH.CA Yearly LT Debt VS Equity VS FCFCPH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.12 indicates that CPH should not have too much problems paying its short term obligations.
  • CPH has a worse Current ratio (1.12) than 77.42% of its industry peers.
  • CPH has a Quick Ratio of 1.12. This is a bad value and indicates that CPH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.79, CPH is doing worse than 67.74% of the companies in the same industry.
  • The current and quick ratio evaluation for CPH is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.79
CPH.CA Yearly Current Assets VS Current LiabilitesCPH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. CPH.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 126.09% over the past year.
  • Measured over the past years, CPH shows a very strong growth in Earnings Per Share. The EPS has been growing by 43.65% on average per year.
  • CPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 51.22%.
  • The Revenue has been growing by 18.48% on average over the past years. This is quite good.
EPS 1Y (TTM)126.09%
EPS 3Y0.69%
EPS 5Y43.65%
EPS Q2Q%292.31%
Revenue 1Y (TTM)51.22%
Revenue growth 3Y34.62%
Revenue growth 5Y18.48%
Sales Q2Q%3.35%

3.2 Future

  • CPH is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.30% yearly.
  • Based on estimates for the next years, CPH will show a quite strong growth in Revenue. The Revenue will grow by 11.81% on average per year.
EPS Next Y-27.65%
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%
EPS Next 5YN/A
Revenue Next Year5.16%
Revenue Next 2Y17.62%
Revenue Next 3Y11.81%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CPH.CA Yearly Revenue VS EstimatesCPH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M
CPH.CA Yearly EPS VS EstimatesCPH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

5

4. CPH.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.75, the valuation of CPH can be described as correct.
  • CPH's Price/Earnings ratio is rather cheap when compared to the industry. CPH is cheaper than 80.65% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.54. CPH is valued rather cheaply when compared to this.
  • CPH is valuated rather expensively with a Price/Forward Earnings ratio of 17.59.
  • Based on the Price/Forward Earnings ratio, CPH is valued a bit cheaper than the industry average as 67.74% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.68, CPH is valued at the same level.
Industry RankSector Rank
PE 12.75
Fwd PE 17.59
CPH.CA Price Earnings VS Forward Price EarningsCPH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPH is on the same level as its industry peers.
  • Based on the Price/Free Cash Flow ratio, CPH is valued a bit cheaper than the industry average as 77.42% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.33
EV/EBITDA 13.94
CPH.CA Per share dataCPH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • CPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.29
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPH.CA Dividend Analysis

5.1 Amount

  • No dividends for CPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPH.CA Fundamentals: All Metrics, Ratios and Statistics

CIPHER PHARMACEUTICALS INC

TSX:CPH (4/29/2026, 7:00:00 PM)

18.1

-0.41 (-2.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength39.37
Industry Growth47.76
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners1.32%
Inst Owner ChangeN/A
Ins Owners3.97%
Ins Owner ChangeN/A
Market Cap457.57M
Revenue(TTM)50.45M
Net Income(TTM)27.33M
Analysts77.5
Price Target19.92 (10.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)146.06%
Min EPS beat(2)66.34%
Max EPS beat(2)225.78%
EPS beat(4)3
Avg EPS beat(4)80.27%
Min EPS beat(4)-7.18%
Max EPS beat(4)225.78%
EPS beat(8)5
Avg EPS beat(8)36.37%
EPS beat(12)9
Avg EPS beat(12)70.11%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.19%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)-2.37%
Revenue beat(4)1
Avg Revenue beat(4)-1.64%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)0.41%
Revenue beat(12)3
Avg Revenue beat(12)2.5%
Revenue beat(16)3
Avg Revenue beat(16)-1.15%
PT rev (1m)1.74%
PT rev (3m)1.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-32.5%
EPS NY rev (1m)25.21%
EPS NY rev (3m)91.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.72%
Revenue NY rev (1m)2.01%
Revenue NY rev (3m)-1.19%
Valuation
Industry RankSector Rank
PE 12.75
Fwd PE 17.59
P/S 6.63
P/FCF 11.33
P/OCF 11.26
P/B 2.65
P/tB 9.1
EV/EBITDA 13.94
EPS(TTM)1.42
EY7.85%
EPS(NY)1.03
Fwd EY5.68%
FCF(TTM)1.6
FCFY8.82%
OCF(TTM)1.61
OCFY8.88%
SpS2.73
BVpS6.83
TBVpS1.99
PEG (NY)N/A
PEG (5Y)0.29
Graham Number14.7708 (-18.39%)
Profitability
Industry RankSector Rank
ROA 17.46%
ROE 21.65%
ROCE 12.83%
ROIC 9.24%
ROICexc 9.8%
ROICexgc 35.19%
OM 33.43%
PM (TTM) 54.17%
GM 80.12%
FCFM 58.52%
ROA(3y)16.09%
ROA(5y)19.87%
ROE(3y)19.41%
ROE(5y)23.95%
ROIC(3y)7.38%
ROIC(5y)11.67%
ROICexc(3y)10.65%
ROICexc(5y)20.81%
ROICexgc(3y)28.57%
ROICexgc(5y)N/A
ROCE(3y)10.25%
ROCE(5y)16.21%
ROICexgc growth 3Y-8.89%
ROICexgc growth 5Y-26.34%
ROICexc growth 3Y-24.04%
ROICexc growth 5Y-22.32%
OM growth 3Y-14.47%
OM growth 5Y-9.91%
PM growth 3Y-25.08%
PM growth 5Y20.8%
GM growth 3Y-0.22%
GM growth 5Y-1.37%
F-Score8
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.19
Debt/EBITDA 0.22
Cap/Depr 2.78%
Cap/Sales 0.4%
Interest Coverage 250
Cash Conversion 123.36%
Profit Quality 108.04%
Current Ratio 1.12
Quick Ratio 0.79
Altman-Z 8.3
F-Score8
WACC8.68%
ROIC/WACC1.06
Cap/Depr(3y)669.05%
Cap/Depr(5y)403.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)126.09%
EPS 3Y0.69%
EPS 5Y43.65%
EPS Q2Q%292.31%
EPS Next Y-27.65%
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%
EPS Next 5YN/A
Revenue 1Y (TTM)51.22%
Revenue growth 3Y34.62%
Revenue growth 5Y18.48%
Sales Q2Q%3.35%
Revenue Next Year5.16%
Revenue Next 2Y17.62%
Revenue Next 3Y11.81%
Revenue Next 5YN/A
EBIT growth 1Y114.98%
EBIT growth 3Y15.14%
EBIT growth 5Y6.74%
EBIT Next Year66.86%
EBIT Next 3Y28.71%
EBIT Next 5YN/A
FCF growth 1Y148.8%
FCF growth 3Y41.15%
FCF growth 5Y21.99%
OCF growth 1Y52.08%
OCF growth 3Y41.11%
OCF growth 5Y20.52%

CIPHER PHARMACEUTICALS INC / CPH.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.


Can you provide the valuation status for CIPHER PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 5 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.


Can you provide the profitability details for CIPHER PHARMACEUTICALS INC?

CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.


What is the earnings growth outlook for CIPHER PHARMACEUTICALS INC?

The Earnings per Share (EPS) of CIPHER PHARMACEUTICALS INC (CPH.CA) is expected to decline by -27.65% in the next year.